Celldex to Present at Upcoming Investor Conferences

Celldex Therapeutics, Inc. (NASDAQ: CLDX), a leader in the development of innovative antibody-based therapies for various immune-related conditions, has announced its participation in several upcoming investor conferences. On November 11, management will engage in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for 10:00 am ET. This will be followed by their appearance at the TD Cowen Immunology & Inflammation Summit on November 13 at 9:30 am ET. The company will also present at the 8th Annual Evercore Healthcare Conference on December 2 at 3:00 pm ET.

These conferences provide a platform for Celldex to share insights about its ongoing research and therapeutic developments, enhancing communication with current and potential investors. Live webcasts of all presentations will be accessible via the "Events & Presentations" section found in the "Investors" area of the Celldex website. For those unable to join the live sessions, replays will be available for 90 days following the events.

Celldex is dedicated to transforming patient care through its pioneering work in immunology. The company focuses on developing life-changing therapies that engage the human immune system to tackle critical pathways associated with allergic, inflammatory, and autoimmune disorders. This commitment to innovation positions Celldex as a valuable player within the healthcare landscape.

For further inquiries, investors can contact Sarah Cavanaugh, Senior Vice President of Corporate Affairs & Administration, at 508-864-8337, or Patrick Till at Meru Advisors at 484-788-8560.

For more information about Celldex and its impactful therapies, visit their official website at www.celldex.com.

As Celldex Therapeutics (NASDAQ: CLDX) prepares for its upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference on November 11, the TD Cowen Immunology & Inflammation Summit on November 13, and the Evercore Healthcare Conference on December 2, investors should consider the following insights and strategies.

Celldex is at the forefront of immunological innovation, with a robust pipeline focused on antibody-based therapies aimed at treating various allergic, inflammatory, and autoimmune disorders. Investors should keep a close watch on the outcomes of these conferences, as management will likely provide updates on clinical trials, partnerships, and potential market launches.

The timing is particularly opportune, as Celldex has been building momentum with its recent advancements. Participating in high-profile conferences enhances visibility not only to institutional investors but also to influential healthcare analysts. This can lead to increased interest in the stock and potential upward pressure on its price if the talks are well-received.

In preparation for these events, investors should consider the following strategies:

1. **Market Sentiment Monitoring:** Pay attention to analysts' forecasts and target prices post-conference. Positive feedback could result in stock price appreciation.

2. **Long-Term Perspective:** With an innovative pipeline, Celldex may offer long-term growth potential, despite near-term volatility. Investors may find value in accumulating shares during any post-conference corrections.

3. **Utilize Webcasts:** Access the live webcasts for insights on strategic direction and management’s emphasis on critical therapeutic advancements. The recordings will also be available for future reference.

In summary, Celldex's participation in these key conferences presents an ideal opportunity for investors to reassess their positions, align with emerging trends in immunotherapy, and capitalize on potential growth avenues. As it stands at a pivotal moment in its corporate journey, prudent investor engagement could yield significant benefits.